GET DAILY SIGNALSMedline (MDLN) Reports +10.4% Sales Growth in Q3 and Raises Full-Year Outlook
Key Takeaways
- Medline reported third-quarter 2026 net sales of $7.86 billion, up 10.4% year over year, with organic sales up 10.5%.
- Adjusted diluted EPS came in at $0.44, above the consensus estimate of $0.35.
- Management raised its full-year 2026 organic sales guidance to 10.0%–10.5%, the third consecutive quarterly increase.
- Adjusted EBITDA rose 11.8% to $960 million, but included $81 million in tariff refunds.
- The company authorized a $1 billion share repurchase program and prepaid $750 million of term loan debt in October.
Why These Results Matter
Medline, the largest provider of medical-surgical products and supply chain solutions in the U.S., went public in December 2025 and has delivered a string of earnings beats since then. This third-quarter report was particularly telling because it showed whether the company could maintain double-digit sales growth amid margin pressures from inflation, shifting product mix, and higher operating costs. I was also watching the profitability trends in the fast-growing Supply Chain Solutions segment, which has expanded quickly but tends to carry thinner margins than the branded business. With many competitors seeing slow or negative growth in their med-surg units, MDLN results provided a useful update on demand from hospitals, surgery centers, and post-acute care providers.
The Quarter in Detail
Medline reported third-quarter 2026 net sales of $7.86 billion, a 10.4% increase year over year and ahead of the roughly $7.72 billion consensus. Organic sales, which exclude acquisitions, divestitures, and foreign-exchange effects, rose 10.5%. Adjusted diluted EPS came in at $0.44, exceeding the $0.35 consensus estimate.
Adjusted EBITDA grew 11.8% to $960 million, with adjusted EBITDA margin up 10 basis points to 12.2%. That figure included an $81 million benefit from IEEPA tariff refunds; excluding those refunds, adjusted EBITDA growth was closer to 2%. GAAP net income slipped 1.2% to $318 million.
By segment, Supply Chain Solutions net sales rose 13.9% to $4.2 billion, but its adjusted EBITDA fell 10.2% to $184 million as its margin narrowed to 4.4% from 5.5%. Medline raised its full-year 2026 organic sales outlook to 10.0%–10.5% from 9.0%–10.0% and reaffirmed adjusted EBITDA guidance of $3.3–$3.4 billion, expecting to land near the midpoint. The company also announced a new $1 billion share repurchase program. I also checked this using Tickeron’s AI Screener to see how MDLN compares to others in the industry.
Market Reaction and Investor Sentiment
MDLN shares rallied sharply following the release, jumping roughly 18% in the trading session as investors responded to the earnings beat, the raised sales outlook, and the newly authorized buyback. The reaction reflected relief that top-line momentum remained strong despite tariff-related noise, inflation tied to elevated oil prices, and product-quality concerns that had weighed on the stock in prior weeks.
Sentiment was tempered somewhat by the composition of the beat. A meaningful portion of the adjusted EBITDA growth stemmed from one-time tariff refunds rather than core operating leverage, and the Supply Chain Solutions segment continued to show margin contraction. Investors also monitored ongoing regulatory scrutiny, including an FDA field safety notice related to Medline-branded beds, which remains a source of headline risk even as the business delivered on its financial targets.
What to Watch Going Forward
Following this report, the key question is whether Medline can convert its strong revenue growth into sustained profit expansion. Management kept its adjusted EBITDA guidance at $3.3–$3.4 billion and indicated it expects to finish near the midpoint, signaling that cost pressures and mix shifts will likely continue into the fourth quarter.
Investors should watch the trajectory of the Supply Chain Solutions margin, which management expects to remain in the mid-4% range for the rest of the year. New prime vendor relationships typically carry lower initial margins due to first-year rebates, so the pace at which Medline converts those customers to higher-margin Medline-brand products will be an important driver.
Inflation tied to elevated oil prices remains a headwind, with management now estimating $80 million in related conflict-driven costs, up from a prior $70 million estimate. The timing of higher-cost inventory flowing through cost of goods sold is expected to weigh more heavily in the fourth quarter.
Finally, capital allocation will be in focus after the $1 billion buyback authorization and the October prepayment of $750 million in term loan debt. With free cash flow of $1.8 billion for the first nine months and net leverage improved to 2.5 times, investors will look for continued progress on debt reduction, margin stabilization, and any updates on regulatory and product-quality remediation efforts.
One Tool That Helps with This Analysis
I find Tickeron’s AI Screener useful when reviewing results like these. It lets me quickly filter stocks by industry, fundamentals, and technical signals to compare MDLN against peers and spot broader trends without spending hours on manual work. The tool has become a regular part of how I prepare for earnings reviews.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for MDLN turns positive, indicating new upward trend
MDLN saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 11 similar instances where the indicator turned positive. In 11 of the 11 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 7 of 9 cases where MDLN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for MDLN just turned positive on November 04, 2026. Looking at past instances where MDLN's MACD turned positive, the stock continued to rise in 6 of 7 cases over the following month. The odds of a continued upward trend are 86%.
MDLN moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDLN advanced for three days, in 39 of 54 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 23 of 43 cases where MDLN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 53%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The 10-day moving average for MDLN crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 3 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
MDLN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.059) is normal, around the industry mean (5.069). P/E Ratio (50.481) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.966) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. MDLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement